Previous 10 | Next 10 |
GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results Up to 63.7% Reduction in Bone Marrow Blast Levels Restores Patient's Endogenous NK Cell Function, Proliferation and Immune Surveillance No Progenitor-derived or Autologous/Allogenic Cell...
Penny Stocks To Watch For March 2021 If You Like The Biotech Sector As we approach the third week of March, penny stocks seem to be on a hot streak. This is a combination of the massive decline in covid cases and the $1.9 trillion stimulus package passing. Also, investors’ fear a...
GT Biopharma to Present at The Virtual 33rd Annual Roth Conference PR Newswire BEVERLY HILLS, Calif. , March 10, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage biopharmaceutical company focused on the development and commercializatio...
Gainers: Auris Medical (EARS) +73%, AnPac Bio-Medical Science ANPC +51%, Second Sight Medical Products (EYES) +29%, Sintx Technologies (SINT) +27%, GT Biopharma (GTBP) +25%.Losers: ACADIA Pharmaceuticals ACAD -48%, Graybug Vision GRA...
Biotech Penny Stocks To Watch Right Now While penny stocks are well-known for volatility, so too are certain sectors. Possibly no other sector has continued its volatile trend throughout history better than biotechnology. With things like tech stocks, of course, R&D plays a role, an...
AnPac Bio-Medical Science (ANPC) +75% after update on cancer detection system CDAPS.Second Sight Medical Products (EYES) +67%.GT Biopharma (GTBP) +45%.Auris Medical Holding Ltd. (EARS) +24%.Taoping Inc. (TAOP) +10% on launching Blockchain Business Division.AirNet Technology (ANTE) +...
Are These Biotech Penny Stocks On Your Watch List Right Now? The tech wreck continues this week, but that hasn’t put a pause on other sectors. Furthermore, the market’s appetite for risk appears to be growing stronger once again. Earlier today, we saw the list of Reddit ...
GT Biopharma (GTBP) announces preclinical results for its ROR1 TriKE product candidate as a prospective therapy for the treatment of prostate cancer.The ROR1 TriKE was evaluated in several preclinical models of prostate cancer, and was found to be effective at promoting NK cell killing o...
GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer PR Newswire BEVERLY HILLS, Calif. , March 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on dis...
GT Biopharma (GTBP) announces the addition of the University of Wisconsin's Madison Carbone Cancer Center as a new clinical trial site for its ongoing GTB-3550 TriKE multicenter Phase I/II trial, testing the treatment in certain patients with acute myeloid leukemia ((AML)).GTB-...
News, Short Squeeze, Breakout and More Instantly...
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025 GTB-5550 TriKE ® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025 GTB-5550 Phase 1 dose escalation basket trial initiation expected in 20...
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company’s common stock at a purcha...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 16.4% to $0.199 on volume of 720,586,242 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 74.8% to $1.8 on volume of 682,362,254 shares Pineapple Energy Inc. (PEGY) rose 80.3% to $0.1...